Evidence map›Paper›PMID 40960515›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Anti-inflammatory effect of pirfenidone compared to dexamethasone in ulcerative colitis model induced by acetic acid in rats: involvement of miR-146a and TLR4/NF-κB signaling.

Hanaa Wanas, Dina M Mekawy, Reham M Raafat Hamed, Ragaey Ahmad Eid, Eman A Abd Elmaogod, Eid N Ali Musa, Mohamed A M Allam, Abdelrahman M Attia, Amr M Galal

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hanaa WanasDepartment of Medical Pharmacology, Faculty of Medicine, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0000-0002-7109-939X
Dina M MekawyDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Badr University in Cairo, Badr City, Egypt.ORCID http://orcid.org/0000-0003-4364-9400
Reham M Raafat HamedDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0000-0002-5526-2134
Ragaey Ahmad EidDepartment of Gastroenterology, Hepatology and Infectious Diseases (Tropical Medicine Department), Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt. ragaeyahmad@med.bsu.edu.eg.ORCID http://orcid.org/0000-0002-3077-8265
Eman A Abd ElmaogodDepartment of Pathology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.ORCID http://orcid.org/0000-0001-9008-5973
Eid N Ali MusaDepartment of Anatomy and Embryology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Mohamed A M AllamDepartment of Physiology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.ORCID http://orcid.org/0000-0001-8398-3484
Abdelrahman M AttiaFaculty of Medicine, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0000-0002-5941-9717
Amr M GalalDepartment of Medical Pharmacology, Faculty of Medicine, Cairo University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ulcerative colitis (UC) is a chronic autoimmune inflammatory condition distinguished by tissue damage in colonic mucosal layers. Several pro-inflammatory cytokines are involved in the immunopathogenesis of UC. Multiple studies showed that Toll-like receptor 4 (TLR4) expression markedly increases in UC patients. Thus, concentrating on this pathway may serve as the foundation for novel drug development targeting for treating or impeding the progression of UC. This study aims to explore the effects of pirfenidone (PRF) versus dexamethasone (DEX) on oxidative stress, tissue injury, inflammation, and fibrosis in a rat model of colitis using both biochemical and histopathological analysis. Colitis was induced by administering a single dose of 3% acetic acid (AA) intrarectally. Control animals received injections of an equivalent volume of 0.9% NaCl. Rats were then treated with either 14 days of DEX (2 mg/kg /day; p.o.) or PRF (100 mg/kg/day; p.o.). Animals were sacrificed on day 21 (7 days for acclimatization + 14 days for treatment), and then, the distal 10 cm of each colon was excised. Subsequently, all tissue samples were assessed for macroscopic damage, pathological findings, and different biochemical markers. Both drugs significantly suppressed the elevated levels of inflammatory markers, including TLR4, IL-1β, myeloid differentiation primary response protein 88 (MyD88), Bcl-2-associated X protein (BAX), nuclear factor kappa (NF-κB), tumor necrosis factor-alpha (TNF-α), microRNA-146a (miR-146a), caspase-3, transforming growth factor-beta (TGF-β), connective tissue growth factor (CTGF), and myeloperoxidase (MPO), compared to the untreated UC Group. Additionally, they significantly elevated B-cell lymphoma 2 (BCL2) and platelet-derived growth factor (PDGF) levels, indicating their potential to mitigate inflammation and promote tissue repair. Histologically, PRF and DEX preserved intestinal structure as compared to the control group. PRF is considered a promising and effective anti-inflammatory alternative in the management of rat models of acetic acid-induced colitis.

Indexed as

Anti-Inflammatory AgentsColitis, UlcerativeDexamethasoneMicroRNAsPyridonesToll-Like Receptor 4Acetic AcidAnimalsColonDisease Models, AnimalMaleNF-kappa BOxidative StressRatsRats, Sprague-DawleySignal TransductionAcetic AcidAnti-Inflammatory AgentsDexamethasoneMicroRNAsMIRN146a microRNA, ratNF-kappa BpirfenidonePyridonesTlr4 protein, ratToll-Like Receptor 4Acetic acidPirfenidoneTLR4, DexamethasoneUlcerative colitis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.